Wyoming Drug Utilization Review (WY-DUR)

School of Pharmacy | College of Health Sciences

News

Preferred Drug List (PDL)

The Wyoming Medicaid Preferred Drug List (PDL) including step utilization for anti-depressant medications and prior authorization information is available at the Wyoming EqualityCare Pharmacy Provider website. To view the current PDL, please visit www.wymedicaid.org.

The Draft 2018 PDL, effective January 1, 2018, is available for review.

Public Comment at Meetings

A new policy for public comment at meetings is effective December 2, 2012.

PhRMA Guidelines and PhRMA Comment Request Form (updated November 5, 2015)

Public Guidelines and Public Comment Request Form (updated November 5, 2015)

Proposed Criteria

The following prior authorization criteria were approved at the February 8, 2018 P & T Committee meeting.

Trelegy, Symproic and Ozempic were all referred to the Department of Health for cost analysis and determination of PDL placement as there was no evidence of a difference in safety or efficacy compared to agents in their respective classes.
Xenazine will be limited to a maximum dose of 50 mg per day.
The Adult ADHD criteria will be implemented effective March 14, 2018. Adult patients will be required to meet DSM-V diagnosis criteria, including demonstrable symptoms in two locations, one of which is school or work.

Comments may be sent by email to alewis13@uwyo.edu or by mail to: Wyoming Drug Utilization Review Board, Dept. 3375, 1000 E. University Avenue, Laramie, WY 82071. Comments should be received prior to April 1, 2018.